Independent group finds multiple myeloma drugs too costly in U.S.

May 6 (Reuters) - U.S. prices for newer multiple myeloma treatments should be cut by as much as 94 percent to justify their value in terms of prolonging life, while there is not enough evidence to assess the health benefit of some, according to an independent nonprofit organization that evaluates the effectiveness of medicines.